Skip to main content
Smart Investors Daily
GSK plc logo

NASDAQ · GSK

GSK plc

Healthcare · Drug Manufacturers - General

$47.82

Down-$0.76 (-1.56%)

Updated Nov 20, 2026, 2:12 AM

SID Score

6.0/10

Composite research score

Smart Money

56/100

Neutral

Market cap
99.39B
P/E ratio
13.41
Dividend yield
3.50%
52-week range
$45.81 – $61.70
Volume
3.33M
Avg. volume
5.18M

Price performance · GSK

GSK price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

GSK closed at $47.82 after 21 trading sessions, down 6.62% for the selected period.

Last close
$47.82
Period change
-6.62%
Period low
$47.82
Period high
$51.54
Daily close
View OHLC price history
GSK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$48.21$48.44$47.68$47.823.33M
Nov 18, 2026$49.03$49.49$48.545$48.582.2M
Nov 17, 2026$49.45$49.78$49.145$49.242.95M
Nov 16, 2026$51.23$51.4299$50.375$50.412.95M
Nov 13, 2026$50.25$50.80$50.13$50.452.78M
Nov 12, 2026$50.97$51.07$50.45$50.642.55M
Nov 11, 2026$50.18$50.64$49.79$50.602.7M
Nov 10, 2026$51.50$51.89$51.015$51.232.62M
Nov 9, 2026$51.19$51.64$50.59$51.543.57M
Nov 6, 2026$49.07$50.74$48.94$50.333.19M
Nov 5, 2026$50.575$51.43$50.26$50.413.06M
Nov 4, 2026$50.825$51.285$50.08$51.155.28M
Nov 3, 2026$49.41$49.565$48.62$48.703.11M
Nov 2, 2026$49.17$49.50$48.90$49.132.65M
Oct 30, 2026$49.84$50.28$49.25$49.514.77M
Oct 29, 2026$48.19$49.11$48.025$48.685.61M
Oct 28, 2026$47.65$49.32$47.355$48.748.12M
Oct 27, 2026$50.80$51.25$50.635$50.944.77M
Oct 26, 2026$50.86$51.235$50.85$51.103.61M
Oct 23, 2026$50.83$50.92$50.29$50.753.18M
Oct 22, 2026$50.29$51.435$49.965$51.214.28M

Latest GSK news

The latest Smart Investors Daily articles mentioning GSK.

GSK research

Overview

Company profile and research snapshot.

Company profile

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$53.00
Implied upside
—
Analysts
7
GSK recent ratings
DateFirmRatingTarget
Jun 8, 2026DeutscheHold—
May 28, 2026JefferiesBuy—
May 27, 2026DeutscheHold—
May 6, 2026DeutscheHold—
May 6, 2026CitigroupNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 13, 2026

GSK (LSE:GSK) Settles Key Vaccine Patent Case And Wins Broad Europe Injunction

GSK (LSE:GSK) reached a cross-licensing agreement with Moderna resolving their COVID-19 vaccine patent dispute in Europe. The pharma group secured a significant injunction against Pfizer-BioNTech covering liposome delivery technology used in RNA vaccines across multiple European markets. Ongoing legal actions and expected appeals around this RNA and liposome IP framework now shape how the largest vaccine makers operate in Europe. This combination of a Moderna settlement and a broad...

Yahoo · Nov 13, 2026

Is GSK (LSE:GSK) A Bargain Following Its New Alamar Collaboration?

How GSK’s new Alamar collaboration reshapes the research story GSK (LSE:GSK) just linked up with Alamar Biosciences on a large proteomics study that aims to match circulating protein patterns with how complex diseases develop and respond to treatment. The project leans on Alamar’s NULISA platform to process more than 60,000 serum samples across respiratory, liver, kidney, neurological and autoimmune conditions, with a focus on richer biomarker data to inform future drug development...

Yahoo · Nov 9, 2026

What GSK (LSE:GSK)'s Cancer And HIV Trial Wins Mean For Shareholders

GSK has recently reported multiple clinical updates, including strong phase II rectal cancer data for Jemperli, durable phase I responses for Mo Rez in ovarian and endometrial cancers, and real world adherence benefits from ViiV Healthcare’s long acting HIV regimen. Together, these oncology and HIV readouts highlight how GSK is trying to build a broader mix of specialty medicines that lean on targeted biologics and long acting injectables rather than older primary care drugs. Next, the focus...

Yahoo · Nov 9, 2026

Why Is GSK (LSE:GSK) Drawing Attention For New Cancer Data And Proteomics?

GSK (LSE:GSK) agreed a major scientific collaboration with Alamar Biosciences to run large-scale proteomic research for precision medicine. New clinical data showed highly encouraging results for Jemperli in rectal cancer patients in an ongoing oncology study. Mo-Rez produced promising trial outcomes in ovarian and endometrial cancer, adding another late-stage oncology asset to GSK's pipeline. The Alamar proteomics deal and early Jemperli and Mo-Rez data sit within a wider picture our...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.